Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastroesophageal Reflux | 5 | 2023 | 836 | 1.510 |
Why?
|
| Feces | 8 | 2024 | 1510 | 1.390 |
Why?
|
| Citrus | 1 | 2024 | 49 | 0.940 |
Why?
|
| Colorectal Neoplasms | 14 | 2024 | 6982 | 0.920 |
Why?
|
| Growth Differentiation Factor 15 | 3 | 2015 | 199 | 0.860 |
Why?
|
| Proton Pump Inhibitors | 2 | 2023 | 552 | 0.730 |
Why?
|
| Fusobacterium nucleatum | 3 | 2024 | 176 | 0.710 |
Why?
|
| Polypharmacy | 2 | 2022 | 307 | 0.650 |
Why?
|
| Tea | 1 | 2019 | 289 | 0.590 |
Why?
|
| Diet | 8 | 2024 | 8088 | 0.510 |
Why?
|
| Cyclooxygenase 2 | 2 | 2015 | 597 | 0.480 |
Why?
|
| Prospective Studies | 29 | 2024 | 54962 | 0.470 |
Why?
|
| Constipation | 2 | 2023 | 570 | 0.470 |
Why?
|
| Depression | 2 | 2024 | 8231 | 0.460 |
Why?
|
| Ascariasis | 1 | 2012 | 13 | 0.420 |
Why?
|
| Ascaris lumbricoides | 1 | 2012 | 10 | 0.410 |
Why?
|
| Trichuriasis | 1 | 2012 | 24 | 0.410 |
Why?
|
| Trichuris | 1 | 2012 | 32 | 0.410 |
Why?
|
| Metagenomics | 5 | 2024 | 474 | 0.400 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2012 | 65 | 0.400 |
Why?
|
| Postmenopause | 2 | 2018 | 2519 | 0.390 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 1119 | 0.350 |
Why?
|
| Cognition | 3 | 2023 | 7081 | 0.350 |
Why?
|
| Dietary Fiber | 4 | 2024 | 767 | 0.330 |
Why?
|
| Feeding Behavior | 3 | 2021 | 3205 | 0.330 |
Why?
|
| Metagenome | 3 | 2024 | 465 | 0.320 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2023 | 2442 | 0.300 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 1890 | 0.290 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 1794 | 0.280 |
Why?
|
| Carcinoma | 1 | 2017 | 2340 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 7478 | 0.250 |
Why?
|
| Gene Expression | 1 | 2018 | 7603 | 0.240 |
Why?
|
| Bacteria | 3 | 2021 | 2216 | 0.230 |
Why?
|
| Monoamine Oxidase | 1 | 2024 | 180 | 0.230 |
Why?
|
| Sulfur | 2 | 2021 | 158 | 0.230 |
Why?
|
| S-Adenosylmethionine | 1 | 2024 | 219 | 0.210 |
Why?
|
| Bacteroides fragilis | 1 | 2024 | 250 | 0.210 |
Why?
|
| Middle Aged | 28 | 2024 | 223737 | 0.210 |
Why?
|
| Risk Factors | 17 | 2024 | 74976 | 0.200 |
Why?
|
| Mesalamine | 1 | 2023 | 134 | 0.200 |
Why?
|
| Health Personnel | 5 | 2021 | 3383 | 0.200 |
Why?
|
| Nurses | 3 | 2023 | 2501 | 0.190 |
Why?
|
| Sulfur-Reducing Bacteria | 1 | 2021 | 14 | 0.190 |
Why?
|
| Sulfur Compounds | 1 | 2021 | 32 | 0.190 |
Why?
|
| Diverticulitis | 1 | 2024 | 187 | 0.190 |
Why?
|
| Proportional Hazards Models | 6 | 2021 | 12562 | 0.190 |
Why?
|
| Humans | 45 | 2024 | 768970 | 0.180 |
Why?
|
| Adenoma | 3 | 2017 | 2163 | 0.180 |
Why?
|
| Adenomatous Polyps | 1 | 2021 | 109 | 0.180 |
Why?
|
| United States | 15 | 2024 | 73186 | 0.170 |
Why?
|
| Inflammation | 3 | 2021 | 10868 | 0.170 |
Why?
|
| Adult | 21 | 2024 | 223851 | 0.170 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 3813 | 0.160 |
Why?
|
| Female | 29 | 2024 | 397515 | 0.160 |
Why?
|
| Glutens | 1 | 2021 | 240 | 0.160 |
Why?
|
| Aged | 20 | 2024 | 171786 | 0.160 |
Why?
|
| Phylogeny | 2 | 2024 | 2843 | 0.160 |
Why?
|
| Masks | 1 | 2021 | 214 | 0.160 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 524 | 0.150 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2023 | 454 | 0.150 |
Why?
|
| Fusobacterium Infections | 1 | 2018 | 54 | 0.150 |
Why?
|
| Risk Assessment | 8 | 2024 | 24333 | 0.150 |
Why?
|
| Aspirin | 2 | 2023 | 3135 | 0.140 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
| Cohort Studies | 6 | 2024 | 41808 | 0.140 |
Why?
|
| Intestinal Diseases | 1 | 2021 | 505 | 0.140 |
Why?
|
| Geriatric Assessment | 2 | 2022 | 1422 | 0.140 |
Why?
|
| Nursing Research | 1 | 2017 | 80 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2021 | 557 | 0.130 |
Why?
|
| Follow-Up Studies | 9 | 2023 | 39394 | 0.130 |
Why?
|
| Diarrhea | 2 | 2023 | 1320 | 0.130 |
Why?
|
| Defecation | 1 | 2017 | 191 | 0.130 |
Why?
|
| Incidence | 5 | 2024 | 21547 | 0.120 |
Why?
|
| Coffee | 1 | 2019 | 594 | 0.120 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 473 | 0.120 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 12095 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2021 | 985 | 0.120 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 9549 | 0.120 |
Why?
|
| Beverages | 1 | 2019 | 819 | 0.110 |
Why?
|
| Fecal Incontinence | 1 | 2017 | 246 | 0.110 |
Why?
|
| Male | 20 | 2024 | 365203 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2022 | 1769 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2017 | 726 | 0.110 |
Why?
|
| Prostaglandins | 1 | 2014 | 398 | 0.110 |
Why?
|
| Ischemia | 1 | 2021 | 1900 | 0.100 |
Why?
|
| Ecuador | 1 | 2012 | 62 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3118 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3241 | 0.100 |
Why?
|
| CpG Islands | 1 | 2017 | 1210 | 0.100 |
Why?
|
| Case-Control Studies | 5 | 2024 | 22296 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 2059 | 0.090 |
Why?
|
| Data Collection | 1 | 2020 | 3324 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 1209 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 14794 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2017 | 1802 | 0.090 |
Why?
|
| Menopause | 1 | 2018 | 1656 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 15471 | 0.080 |
Why?
|
| Adiponectin | 1 | 2015 | 1117 | 0.080 |
Why?
|
| Time Factors | 5 | 2021 | 40261 | 0.080 |
Why?
|
| Colitis | 1 | 2018 | 1242 | 0.080 |
Why?
|
| Neuropsychological Tests | 1 | 2022 | 7148 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2017 | 1410 | 0.080 |
Why?
|
| Women's Health | 1 | 2018 | 2081 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 26395 | 0.070 |
Why?
|
| Sex Factors | 4 | 2024 | 10633 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2012 | 1183 | 0.070 |
Why?
|
| Prognosis | 3 | 2017 | 30046 | 0.070 |
Why?
|
| Diet Surveys | 2 | 2021 | 1160 | 0.070 |
Why?
|
| Pandemics | 3 | 2022 | 8749 | 0.070 |
Why?
|
| Comorbidity | 1 | 2021 | 10592 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2015 | 4148 | 0.060 |
Why?
|
| Software | 1 | 2020 | 4479 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3671 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2022 | 42683 | 0.060 |
Why?
|
| Bilophila | 1 | 2024 | 12 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2017 | 9684 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 1811 | 0.060 |
Why?
|
| Actinobacteria | 1 | 2024 | 62 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2276 | 0.060 |
Why?
|
| Age Factors | 4 | 2021 | 18435 | 0.050 |
Why?
|
| DNA Methylation | 1 | 2017 | 4432 | 0.050 |
Why?
|
| Israel | 1 | 2024 | 726 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2024 | 399 | 0.050 |
Why?
|
| Escherichia coli | 2 | 2024 | 4213 | 0.050 |
Why?
|
| Psychomotor Agitation | 1 | 2023 | 307 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 12253 | 0.040 |
Why?
|
| Hydrogen Sulfide | 1 | 2021 | 147 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 59739 | 0.040 |
Why?
|
| Laparotomy | 1 | 2021 | 459 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2021 | 301 | 0.040 |
Why?
|
| Logistic Models | 1 | 2014 | 13318 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2023 | 65480 | 0.040 |
Why?
|
| China | 1 | 2024 | 2395 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 906 | 0.040 |
Why?
|
| Massachusetts | 2 | 2021 | 8894 | 0.040 |
Why?
|
| Independent Living | 1 | 2022 | 584 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 13698 | 0.040 |
Why?
|
| Public Health | 2 | 2021 | 2680 | 0.040 |
Why?
|
| Europe | 1 | 2024 | 3441 | 0.040 |
Why?
|
| Metabolome | 1 | 2024 | 1009 | 0.030 |
Why?
|
| C-Reactive Protein | 2 | 2021 | 3859 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2022 | 781 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15661 | 0.030 |
Why?
|
| Fruit | 1 | 2021 | 1165 | 0.030 |
Why?
|
| Vegetables | 1 | 2021 | 1199 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2022 | 857 | 0.030 |
Why?
|
| Disease Transmission, Infectious | 1 | 2021 | 560 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.030 |
Why?
|
| Metabolomics | 1 | 2024 | 1675 | 0.030 |
Why?
|
| Age of Onset | 1 | 2021 | 3346 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2015 | 348 | 0.030 |
Why?
|
| Weight Gain | 1 | 2023 | 2359 | 0.030 |
Why?
|
| Body Weight | 1 | 2023 | 4628 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 30266 | 0.020 |
Why?
|
| Cause of Death | 1 | 2022 | 3721 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 22389 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2024 | 3840 | 0.020 |
Why?
|
| Young Adult | 3 | 2023 | 60131 | 0.020 |
Why?
|
| Pregnancy | 1 | 2012 | 30265 | 0.020 |
Why?
|
| Infant | 1 | 2012 | 36556 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 1752 | 0.020 |
Why?
|
| Self Report | 1 | 2020 | 3773 | 0.020 |
Why?
|
| Mental Health | 1 | 2022 | 3275 | 0.020 |
Why?
|
| Colon | 1 | 2015 | 1803 | 0.020 |
Why?
|
| Exercise | 1 | 2023 | 5954 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2021 | 9384 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2015 | 3232 | 0.020 |
Why?
|
| Models, Biological | 1 | 2020 | 9499 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2015 | 10115 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14752 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 13091 | 0.010 |
Why?
|
| Animals | 1 | 2012 | 169335 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2020 | 81903 | 0.010 |
Why?
|
Concepts
(173)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(78)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_